BRÈVE

sur SENSORION (EPA:ALSEN)

Sensorion Announces Appointment of New Chief Financial Officer

Montpellier, June 27, 2024 - Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on innovative therapies for hearing loss disorders, has named Laurene Danon as its new Chief Financial Officer.

Danon brings over 15 years of experience in investment banking and equity capital markets. A graduate of HEC, her career includes roles at J.P. Morgan and Jefferies International before founding Concorde Advisory. She has managed over 70 transactions, raising more than $35 billion.

Previously advising Sensorion on capital increases, Danon expressed enthusiasm about joining Sensorion during a pivotal period marked by advancements in its gene therapy programs.

Nawal Ouzren, CEO of Sensorion, highlighted Danon's significant expertise in international capital markets as a vital addition to the team to support the company's mission to develop therapies for hearing disorders.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SENSORION